enVVeno Medical Corporation (NVNO)
| Market Cap | 7.09M -92.6% |
| Revenue (ttm) | n/a |
| Net Income | -15.72M |
| EPS | -24.90 |
| Shares Out | 682.72K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 26,941 |
| Open | 10.44 |
| Previous Close | 10.48 |
| Day's Range | 10.17 - 11.59 |
| 52-Week Range | 8.67 - 49.35 |
| Beta | 1.06 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 31, 2026 |
About NVNO
enVVeno Medical Corporation, a medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease in the United States. The company’s lead product is the VenoValve, a surgical replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The company also develops enVVe, a non-surgical and transcathe... [Read more]
Financial Performance
Financial StatementsNews
enVVeno announces publication of independent health economic study
enVVeno Medical (NVNO) highlighted the publication of a landmark, peer-reviewed health economic analysis in the Journal of Vascular Surgery: Venous and Lymphatic Disorders demonstrating the potential ...
Independent Health Economic Study Recently Published in Journal of Vascular Surgery Reports Economic Dominance of enVVeno Medical's Replacement Venous Valve Therapy Compared to Standard of Care Treatments
Published economic health study shows both short- and long-term cost-effectiveness of replacement venous value therapy versus standard-of-care treatments for deep venous CVI, generating compelling evi...
enVVeno Medical reports Q2 EPS ($5.37) vs. ($11.52) last year
“The second quarter represented a defining milestone for enVVeno, as we got the approval to move forward with the pivotal study for enVVe, our non-surgical replacement venous valve. enVVe has…
enVVeno Medical sees cash runway into 3Q27
As of June 30, 2026, the Company had total cash and investments of approximately $21.5M, comprising $2.8M in cash and cash equivalents and $18.7M in short-term investments. Published first on…
enVVeno Medical expects cash burn rate of $4M-$5M per quarter in 2H26
Cash burn for the second quarter was $3.4M, consistent with the Company’s projected cash burn rate of approximately $3M to $4M per quarter. The Company anticipates that its cash burn…
enVVeno Medical Reports Second Quarter 2026 Financial Results and Advances Towards FDA Pivotal Trial for First-in-Class Non-Surgical Replacement Venous Valve
Company Enters the Second Half of 2026 With Tailwinds From an FDA IDE Approval, With the TAVVE Pivotal Study Expected to Begin Enrolling Patients During the Second Half of This Year and Cash Runway Ex...
enVVeno Medical highlights newly issued U.S. patent
enVVeno Medical (NVNO) announced that Robert Berman, Chief Executive Officer of enVVeno Medical participated in a Virtual Investor “What This Means” segment. As part of the segment, Berman discussed t...
enVVeno Medical Highlights Newly Issued U.S. Patent Strengthening Competitive Position Ahead of Historic Pivotal Trial in Virtual Investor "What This Means" Segment
CEO Explains How Broad Patent Protection, Combined with First-Ever FDA IDE Approval, Positions enVVe® to Own a Multi-Billion-Dollar Venous Disease Market Watch the "What This Means" video here IRVINE,...
enVVeno Medical secures U.S. patent for enVVe system
enVVeno Medical (NVNO) announced the issuance of U.S. Patent No. 12,575,932, further expanding its intellectual property portfolio supporting its enVVe transcatheter replacement venous valve system fo...
enVVeno Medical Secures Transformational U.S. Patent for enVVe System, Strengthening Competitive Moat Ahead of Launch of Historic FDA Pivotal Trial
New Patent Broadly Protects Core Technology Behind Potential First Non-Surgical Replacement Venous Valve Builds on First-Ever FDA IDE Approval for Pivotal Study of enVVe System Targeting Multi-Billio...
enVVeno Medical upgraded to Buy from Neutral at Ladenburg
Ladenburg upgraded enVVeno Medical (NVNO) to Buy from Neutral with a $30 price target
enVVeno Medical to Present in the Webull Corporate Connect Webinar Series
- Live webcast on Wednesday, June 24th at 2:00 PM ET - Access the event here IRVINE, CA / ACCESS Newswire / June 22, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"),a com...
enVVeno Medical to Participate in the Virtual Investor Closing Bell Series
Live video webcast with Robert Berman, Chief Executive Officer of enVVeno Medical, on Tuesday, June 9that 4:00 PM ET Register here IRVINE, CA / ACCESS Newswire / June 2, 2026 / enVVeno Medical Corpora...
enVVeno Medical Discusses FDA IDE Approval in Virtual Investor "What This Means" Segment
First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-surgical Replacement Venous Valve IDE approval positions enVVeno to advance what could become the first effective treatment option for the...
enVVeno Medical reports Q1 EPS ($5.89) vs. ($7.75) last year
“With a strong balance sheet, significant physician interest in the enVVe valve, and a clearly defined regulatory pathway, we are well positioned to execute the TAVVE study and advance the…
enVVeno Medical sees cash runway into 3Q27
Cash and investments totaled $24.9 million as of March 31, 2026, compared to $28.2 million as of December 31, 2025. The Company believes its current cash and investment resources are…
enVVeno Medical says cash burn rate may increase to $4M-$5M per quarter
The Company anticipates that its cash burn rate may increase to approximately $4 million to $5 million per quarter in 2026 as it prepares for and initiates the TAVVE pivotal…
enVVeno Medical Reports First Quarter 2026 Financial Results and Provides Business Update Highlighting Strategic Advancement of the enVVe System
Company ended the first quarter with approximately $25 million in cash and investments Capital on hand should fund operations through multiple key milestones into Q3 2027 Company recently received FDA...
enVVeno Medical announces FDA awarded IDE approval to proceed with TAVVEB study
enVVeno Medical (NVNO) announced that the U.S. Food and Drug Administration, FDA, has awarded the Company the first-ever IDE approval to proceed with a U.S. pivotal study of a non-surgical…
enVVeno Medical Receives First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-Surgical Replacement Venous Valve
First-in-Class enVVe system to be evaluated in TAVVE U.S. Pivotal Trial Clinical site activation and patient enrollment expected to commence later this year Large unmet clinical need for approximately...
enVVeno Medical reports FY25 EPS ($33.06) vs. ($44.53) last year
Robert Berman, CEO, stated, “2025 represented a significant inflection point for the Company. Following the FDA’s decision regarding the VenoValve, we made the strategic determination to accelerate de...
enVVeno Medical expects cash burn rate of $4M-$5M per quarter in 2026
The Company expects its cash burn rate to increase modestly in 2026 to approximately $4M to $5M per quarter as it prepares for and initiates the enVVe system pivotal trial.
enVVeno Medical Reports Full Year 2025 Financial Results and Highlights Strategic Advancement of enVVe(R) System
Company accelerated development of the enVVe® System, completing pre-clinical studies and progressing toward a 2026 pivotal trial initiation Strong financial position expected to provide an operating ...
NorthStrive Fund II LP Calls on enVVeno Medical to Halt Clinical Spending Plans and Call Special Shareholder Meeting to Vote on Strategic Alternatives
NEWPORT BEACH, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- NorthStrive Fund II LP (“NorthStrive Fund II”), a subsidiary of NorthStrive Companies Inc., headquartered in Newport Beach, California, and be...
enVVeno Medical regains compliance with Nasdaq minimum bid price rule
enVVeno Medical (NVNO) has received formal notice from the Listings Qualifications staff of The Nasdaq Stock Marketthat the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which r...